[go: up one dir, main page]

WO2006002106A3 - Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide - Google Patents

Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide Download PDF

Info

Publication number
WO2006002106A3
WO2006002106A3 PCT/US2005/021827 US2005021827W WO2006002106A3 WO 2006002106 A3 WO2006002106 A3 WO 2006002106A3 US 2005021827 W US2005021827 W US 2005021827W WO 2006002106 A3 WO2006002106 A3 WO 2006002106A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
drugs
polysaccharide
delivery
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/021827
Other languages
French (fr)
Other versions
WO2006002106A2 (en
Inventor
David Platt
Eliezer Zomer
Anatole Klyosov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pro Pharmaceuticals Inc
Original Assignee
Pro Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Pharmaceuticals Inc filed Critical Pro Pharmaceuticals Inc
Priority to EP05786102A priority Critical patent/EP1765365A4/en
Priority to JP2007518186A priority patent/JP2008503583A/en
Priority to BRPI0512394-1A priority patent/BRPI0512394A/en
Priority to CA002570570A priority patent/CA2570570A1/en
Publication of WO2006002106A2 publication Critical patent/WO2006002106A2/en
Publication of WO2006002106A3 publication Critical patent/WO2006002106A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed herein are chemically soluble ligand branched polysaccharides having a molecular weight in the range of about 50 kD to about 200 kD in combination with one or more therapeutic agents. Also disclosed are methods for using the same in combination with at least one anti-cancer drug for treating and preventing malignant cancer. Additionally methods for using the composition for treating and preventing angiogenesis is disclosed.
PCT/US2005/021827 2004-06-22 2005-06-21 Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide Ceased WO2006002106A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP05786102A EP1765365A4 (en) 2004-06-22 2005-06-21 Compositions and methods ofr the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide
JP2007518186A JP2008503583A (en) 2004-06-22 2005-06-21 Compositions and methods for co-delivery of anti-cancer agents, anti-angiogenic agents, and polysaccharides
BRPI0512394-1A BRPI0512394A (en) 2004-06-22 2005-06-21 compositions and methods for co-distribution of anticancer drugs, antiangiogenic drugs and a polysaccharide
CA002570570A CA2570570A1 (en) 2004-06-22 2005-06-21 Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58195804P 2004-06-22 2004-06-22
US60/581,958 2004-06-22

Publications (2)

Publication Number Publication Date
WO2006002106A2 WO2006002106A2 (en) 2006-01-05
WO2006002106A3 true WO2006002106A3 (en) 2006-10-19

Family

ID=35782284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/021827 Ceased WO2006002106A2 (en) 2004-06-22 2005-06-21 Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide

Country Status (6)

Country Link
EP (1) EP1765365A4 (en)
JP (1) JP2008503583A (en)
CN (1) CN101267828A (en)
BR (1) BRPI0512394A (en)
CA (1) CA2570570A1 (en)
WO (1) WO2006002106A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102088995B (en) 2008-05-14 2016-01-20 维多利亚农业服务控股公司 Angiogenin and angiogenin agonist are used for the treatment of the purposes of disease and obstacle
AU2013204721B2 (en) * 2008-05-14 2016-08-18 Agriculture Victoria Services Pty Ltd Methods for treating cachexia
CZ302789B6 (en) 2009-11-25 2011-11-09 Zentiva, K. S. Method of increasing solubility of pharmaceutically active compounds and targeted (controlled) transport thereof into intestine
AU2013204740C1 (en) * 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
FR3022462B1 (en) * 2014-06-18 2018-04-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies ORAL COMPOSITION OF ANTI-TNFALPHA ANTIBODY

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020107222A1 (en) * 1993-03-01 2002-08-08 David Platt Modified polysaccharides for treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
EP0958825A1 (en) * 1998-05-18 1999-11-24 Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) Synergistic composition of a non-digestible carbohydrate and an anti-cancer drug for use in the treatment of cancer
AU778178B2 (en) * 1999-09-06 2004-11-18 Gunther Beisel Cross-linked agent for generation of a long-lasting satiety effect and method for the production of the said
ES2376739T3 (en) * 2001-03-27 2012-03-16 Galectin Therapeutics Inc. Joint administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
KR20040045795A (en) * 2002-11-25 2004-06-02 주식회사한국신약 Anti-cancer agent comprising polysaccharide obtained from mycelia of Phellinus linteus and mitomycine C

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020107222A1 (en) * 1993-03-01 2002-08-08 David Platt Modified polysaccharides for treatment of cancer

Also Published As

Publication number Publication date
BRPI0512394A (en) 2008-03-11
JP2008503583A (en) 2008-02-07
EP1765365A2 (en) 2007-03-28
CA2570570A1 (en) 2006-01-05
WO2006002106A2 (en) 2006-01-05
EP1765365A4 (en) 2008-02-20
CN101267828A (en) 2008-09-17

Similar Documents

Publication Publication Date Title
Vogus et al. A review on engineering polymer drug conjugates to improve combination chemotherapy
Pasut et al. PEG conjugates in clinical development or use as anticancer agents: an overview
AU2001275651A1 (en) Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same
WO2004073656A3 (en) Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
WO2003072754A3 (en) Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
WO2002020663A3 (en) Degradable polyacetal polymers
NO20013402D0 (en) Methods for the treatment of ovarian cancer, poly (phosphoester) preparations, and biodegradable articles thereof
WO2007047291A3 (en) Anti-glypican-3 antibody
NZ590569A (en) Factor viii polymer conjugates
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
NZ588913A (en) Liver cancer drug
AU2874099A (en) Low molecular weight compounds administered together with anti-cancer agents to treat cancer and pharmaceutical compositions thereof
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
WO2001062235A3 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
WO2008002460A3 (en) Orally available light-independent antineoplastic compounds
Shahab et al. Vascular toxicity of antineoplastic agents
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
WO2006002106A3 (en) Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide
WO2002056835A3 (en) Anticancer treatment using triptolide prodrugs
WO2003097106A3 (en) Drug conjugate comprising an erythropoietin receptor ligand and an anticancer agent
WO2007146417A3 (en) Glucan compositions and methods of enhancing cr3 dependent neutrophil-mediated cytotoxicity
WO2008089185A3 (en) Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof
DK1383516T3 (en) Administration of a polysaccharide concomitantly with a chemotherapeutic agent for the treatment of cancer
Rosenthal et al. Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil
WO2005002516A3 (en) Leukocyte internalized peptide-drug conjugates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2570570

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005786102

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007518186

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580020707.8

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005786102

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0512394

Country of ref document: BR